Amicus Therapeutics is a US-based pharmaceutical company with a focus on developing medicines for rare metabolic diseases. They have a pipeline of products including oral precision medicine for Fabry disease and a gene therapy portfolio. With a medium ESG risk rating of 27.5, Amicus Therapeutics is dedicated to discovering, developing, and delivering advanced therapies for rare and orphan diseases.